458,684 Shares in Exelixis, Inc. (EXEL) Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 458,684 shares of the biotechnology company’s stock, valued at approximately $13,944,000. Stephens Investment Management Group LLC owned 0.16% of Exelixis as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of EXEL. American Century Companies Inc. grew its holdings in shares of Exelixis by 426.4% during the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock worth $44,686,000 after purchasing an additional 1,190,691 shares during the period. Jennison Associates LLC grew its holdings in shares of Exelixis by 38.1% during the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock worth $128,554,000 after purchasing an additional 1,167,758 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Exelixis during the 2nd quarter worth about $28,689,000. Macquarie Group Ltd. grew its holdings in shares of Exelixis by 811.5% during the 3rd quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock worth $30,928,000 after purchasing an additional 1,136,409 shares during the period. Finally, First Trust Advisors LP grew its holdings in shares of Exelixis by 588.9% during the 3rd quarter. First Trust Advisors LP now owns 1,086,135 shares of the biotechnology company’s stock worth $26,317,000 after purchasing an additional 928,475 shares during the period. Institutional investors and hedge funds own 81.43% of the company’s stock.

Shares of Exelixis, Inc. (EXEL) traded up $0.74 on Thursday, hitting $29.54. The company’s stock had a trading volume of 1,616,000 shares, compared to its average volume of 2,819,085. Exelixis, Inc. has a one year low of $18.03 and a one year high of $32.50. The firm has a market cap of $8,740.00, a price-to-earnings ratio of 61.08, a price-to-earnings-growth ratio of 0.81 and a beta of 1.84.

A number of equities analysts have weighed in on the company. Oppenheimer restated a “hold” rating on shares of Exelixis in a report on Wednesday, January 17th. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a report on Tuesday, January 2nd. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Wednesday, October 18th. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Cann restated a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $32.13.

In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the transaction, the director now directly owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “458,684 Shares in Exelixis, Inc. (EXEL) Acquired by Stephens Investment Management Group LLC” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://weekherald.com/2018/02/15/stephens-investment-management-group-llc-takes-13-94-million-position-in-exelixis-inc-exel.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply